VERU Jun 2024 0.500 call
| Previous close | 0.4100 |
| Open | 0.4100 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 0.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.4000 - 0.4100 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireVeru to Present at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida. The presentations are: Pooled Safety Ana
Simply Wall St.Individual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%
Key Insights Veru's significant individual investors ownership suggests that the key decisions are influenced by...
- GlobeNewswire
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss whe
